Products - Blood conditions | Topic

Showing 11 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
Product type:
Guidance
Programme:
NICE guideline
Published date:
23 May 2019
Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2019
Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2020
Andexanet alfa for reversing anticoagulation [ID1101]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 March 2020
Patiromer for treating hyperkalaemia [ID877]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura ID1185
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Voxelotor for treating sickle cell disease [ID1403]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 11 products

Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]

Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

Andexanet alfa for reversing anticoagulation [ID1101]

Patiromer for treating hyperkalaemia [ID877]

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura ID1185

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

Voxelotor for treating sickle cell disease [ID1403]

Blood conditions Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 11 products

Product type
1 selected

New and updated
1 selected